Pharvaris Presents Data at the Bradykinin Symposium 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer
September 6, 2024 5:07 AM EDTOppenheimer analyst Justin Kim raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $42.00 (from $38.00) while maintaining a Outperform rating.
The analyst comments "On Thursday PHVS presented 2 oral presentations and 10 posters at the bradykinin symposium focused on HAE. Critical to the PHVS... More
